Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific
- PMID: 20560868
- DOI: 10.3109/00365548.2010.496087
Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific
Abstract
In New Caledonia, South Pacific, Acinetobacter baumannii is a nosocomial pathogen. OXA-23 carbapenem-resistant A. baumannii (CRAB) has been ranked third among all multidrug-resistant (MDR) bacteria at the main hospital of Nouméa in New Caledonia (24.8%, 50/202 isolates). In the present study, risk factors and outcomes for 50 patients with CRAB infection were compared with those of 152 patients infected with other MDR bacteria. Independent risk factors for infection with CRAB were respiratory ward admission (odds ratio 2.8, 95% confidence interval 1.1-7.1) and previous treatment with quinolones, β-lactams and anti-MRSA antibiotics. The 30-day mortality was higher for CRAB infections compared with other MDR infections (14% vs 3.3%, p = 0.006). These findings highlight the importance of knowing specific local characteristics relating to the ecology and patterns of resistance of MDR bacteria so as to avoid the emergence of unexpected pan-resistant bacteria.
Similar articles
-
Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.Southeast Asian J Trop Med Public Health. 2011 May;42(3):693-703. Southeast Asian J Trop Med Public Health. 2011. PMID: 21706949
-
Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in New Caledonia.Clin Microbiol Infect. 2008 Oct;14(10):977-81. doi: 10.1111/j.1469-0691.2008.02068.x. Clin Microbiol Infect. 2008. PMID: 18828857
-
A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.Clin Microbiol Infect. 2014 Dec;20(12):O1028-34. doi: 10.1111/1469-0691.12716. Epub 2014 Aug 11. Clin Microbiol Infect. 2014. PMID: 24930471
-
Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.Int J Antimicrob Agents. 2012 Feb;39(2):105-14. doi: 10.1016/j.ijantimicag.2011.10.004. Epub 2011 Nov 22. Int J Antimicrob Agents. 2012. PMID: 22113193 Review.
-
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.Clin Microbiol Infect. 2006 Sep;12(9):826-36. doi: 10.1111/j.1469-0691.2006.01456.x. Clin Microbiol Infect. 2006. PMID: 16882287 Review.
Cited by
-
Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand.Antibiotics (Basel). 2022 Jan 23;11(2):143. doi: 10.3390/antibiotics11020143. Antibiotics (Basel). 2022. PMID: 35203746 Free PMC article.
-
Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection.Exp Ther Med. 2016 Apr;11(4):1345-1347. doi: 10.3892/etm.2016.3051. Epub 2016 Feb 8. Exp Ther Med. 2016. PMID: 27073447 Free PMC article.
-
Epidemiology and Cytokine Levels among Children with Nosocomial Multidrug-Resistant Acinetobacter baumannii Complex in a Tertiary Hospital of Eastern China.PLoS One. 2016 Aug 31;11(8):e0161690. doi: 10.1371/journal.pone.0161690. eCollection 2016. PLoS One. 2016. PMID: 27579592 Free PMC article. Clinical Trial.
-
Molecular identification of Acinetobacter baumannii isolated from intensive care units and their antimicrobial resistance patterns.Adv Biomed Res. 2015 May 29;4:110. doi: 10.4103/2277-9175.157826. eCollection 2015. Adv Biomed Res. 2015. PMID: 26261812 Free PMC article.
-
Deciphering Multidrug-Resistant Acinetobacter baumannii from a Pediatric Cancer Hospital in Egypt.mSphere. 2021 Dec 22;6(6):e0072521. doi: 10.1128/mSphere.00725-21. Epub 2021 Nov 17. mSphere. 2021. PMID: 34787450 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical